WHO Drug Information Vol. 25, No. 2, 2011

More documents

Recommendations

Info

Proposed INN: List 105 WHO Drug Information Vol. 25, No. 2, 2011naloxegol4,5α-epoxi-6α-[(3,6,9,12,15,18,21-heptaoxadocosa-1-il)oxi]-17-(prop-2-en-1-il)morfinan-3,14-diolantagonista de los receptores µ de opiáceosC 34 H 53 NO 11 854601-70-0HNCH 2HOHOOHO HOOH 3 COOOOOnarnatumabum #narnatumabnarnatumabimmunoglobulin G1-kappa, anti-[Homo sapiens MST1R(macrophage stimulating 1 receptor, macrophage stimulating proteinreceptor, MSP receptor, c-met-related tyrosine kinase, proteintyrosinekinase 8, PTK8, RON, p185-Ron, CD136)], Homo sapiensmonoclonal antibody;gamma1 heavy chain (1-452) [Homo sapiens VH (IGHV3-7*01(95.90%) -(IGHD)-IGHJ6*01 T127>I (119)) [8.8.15] (1-122) -IGHG1*03 (123-452)], (225-214')-disulfide with kappa light chain(1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (231-231'':234-234'')-bisdisulfide dimerimmunomodulator, antineoplasticimmunoglobuline G1-kappa, anti-[Homo sapiens MST1R (récepteur1 stimulant le macrophage, récepteur de la protéine stimulant lemacrophage, récepteur de la MSP, tyrosine kinase apparentée àc-met, protéine-tyrosine kinase 8, PTK8, RON, p185-Ron, CD136)],Homo sapiens anticorps monoclonal;chaîne lourde gamma1 (1-452) [Homo sapiens VH (IGHV3-7*01(95.90%) -(IGHD)-IGHJ6*01 T127>I (119)) [8.8.15] (1-122) -IGHG1*03 (123-452)], (225-214')-disulfure avec la chaîne légèrekappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (231-231'':234-234'')-bisdisulfureimmunomodulateur, antinéoplasiquenarnatumab inmunoglobulina G1-kappa, anti-[Homo sapiens MST1R (receptor 1estimulante el macrófago, receptor de la proteína estimulante elmacrófago, receptor de la MSP, tirosina kinasa relacionada conc-met, proteína-tirosina kinase 8, PTK8, RON, p185-Ron, CD136)],Homo sapiens anticuerpo monoclonal;cadena pesada gamma1 (1-452) [Homo sapiens VH (IGHV3-7*01(95.90%) -(IGHD)-IGHJ6*01 T127>I (119)) [8.8.15] (1-122) -IGHG1*03 (123-452)], (225-214')-disulfuro con la cadena ligerakappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (231-231'':234-234'')-bisdisulfuroinmunomodulador, antineoplásico182
WHO Drug Information Vol. 25, No. 2, 2011 Proposed INN: List 1051188275-92-4Heavy chain / Chaîne lourde / Cadena pesadaEVQLVESGGG LVQPGGSLRL SCAASGFTFS SYLMTWVRQA PGKGLEWVAN 50IKQDGSEKYY VDSVKGRFTI SRDNAKNSLN LQMNSLRAED TAVYYCTRDG 100YSSGRHYGMD VWGQGTTVIV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450GK 452Light chain / Chaîne légère / Cadena ligeraEIVLTQSPAT LSLSPGERAT LSCRASQSVS RYLAWYQQKP GQAPRLLIYD 50ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPRTFGQ 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-96 149-2105 266-326 372-43022''-96'' 149''-205'' 266''-326'' 372''-430''Intra-L 23'-88' 134'-194'23'''-88''' 134'''-194'''Inter-H-L 225-214' 225''-214'''Inter-H-H 231-231'' 234-234''N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación302, 302''navarixinumnavarixinnavarixinenavarixina2-hydroxy-N,N-dimethyl-3-[(2-{[(1R)-1-(5-methylfuran-2-yl)propyl]amino}-3,4-dioxocyclobut-1-en-1-yl)amino]benzamideanti-inflammatory action through the inhibition of cytokine (IL-8)2-hydroxy-N,N-diméthyl-3-[(2-{[(1R)-1-(5-méthylfuran-2-yl)propyl]amino}-3,4-dioxocyclobut-1-én-1-yl)amino]benzamideanti-inflammatoire (inhibiteur de l'interleukine 8)2-hidroxi-N,N-dimetil-3-[(2-{[(1R)-1-(5-metilfuran-2-il)propil]amino}-3,4-dioxociclobut-1-en-1-il)amino]benzamidainhibidor de citokina (interleukina-8) con acción antiinflamatoriaC 21 H 23 N 3 O 5 473727-83-2H 3 COH 3 CHONHONHOHOCH 3NCH3nelociguatumnelociguatnélociguatnelociguatmethyl (4,6-diamino-2-{1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}pyrimidin-5-yl)carbamateguanylate cyclase activator(4,6-diamino-2-{1-[(2-fluorophényl)méthyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}pyrimidin-5-yl)carbamate de méthyleactivateur de la guanylate cyclase(4,6-diamino-2-{1-[(2-fluorofenil)metil]-1H-pirazolo[3,4-b]piridin-3-il}pirimidin-5-il)carbamato de metiloactivador de la guanilato ciclasa183
Page 1 and 2:
WHO Drug Information Vol. 25, No. 2
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34: WHO Drug Information Vol. 25, No. 2
Page 83: WHO Drug Information Vol. 25, No. 2
show all

WHO Drug Information Vol. 25, No. 2, 2011

Create successful ePaper yourself

Delete template?

Save as template?